Sign in to view content

Anti-VEGF Resistant Subretinal Fluid Associated With Reduced Risk of Macular Atrophy and Better Vision: Drug-Induced Choroidal New Vessel Homeostasis?

Marco A. Zarbin, MD, PhD

Video
Published 2020

Related

GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Impact of Baseline Imbalances on the Efficacy of Pegcetacoplan for the Treatment of GA: A Post Hoc Analysis of OAKS, DERBY, and FILLY
Sunir J. Garg, MD, FACS, FASRS
Updates from the Field
2022
Mitochondria-Targeted Drug Elamipretide for Treatment of Vision Loss in Dry AMD With Noncentral Geographic Atrophy
Scott W. Cousins, MD
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more